CA2821908C - Novel biomarker and uses thereof in diagnosis, treatment of autism - Google Patents
Novel biomarker and uses thereof in diagnosis, treatment of autism Download PDFInfo
- Publication number
- CA2821908C CA2821908C CA2821908A CA2821908A CA2821908C CA 2821908 C CA2821908 C CA 2821908C CA 2821908 A CA2821908 A CA 2821908A CA 2821908 A CA2821908 A CA 2821908A CA 2821908 C CA2821908 C CA 2821908C
- Authority
- CA
- Canada
- Prior art keywords
- sample
- peptide
- subject
- determining
- autism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 26
- 206010003805 Autism Diseases 0.000 title abstract description 77
- 208000020706 Autistic disease Diseases 0.000 title abstract description 77
- 239000000101 novel biomarker Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 239000000523 sample Substances 0.000 claims description 118
- 230000000694 effects Effects 0.000 claims description 40
- 208000029560 autism spectrum disease Diseases 0.000 claims description 35
- 238000004458 analytical method Methods 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 230000004931 aggregating effect Effects 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 206010003445 Ascites Diseases 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 230000004797 therapeutic response Effects 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 230000000984 immunochemical effect Effects 0.000 claims description 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 230000000926 neurological effect Effects 0.000 abstract description 12
- 239000004475 Arginine Substances 0.000 abstract description 6
- 229940123275 Complement factor I inhibitor Drugs 0.000 abstract description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 6
- 210000004899 c-terminal region Anatomy 0.000 abstract description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract description 4
- 102000003689 Complement Factor I Human genes 0.000 description 24
- 108090000044 Complement Factor I Proteins 0.000 description 24
- 239000003550 marker Substances 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 238000002366 time-of-flight method Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 102100023795 Elafin Human genes 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 102100022133 Complement C3 Human genes 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 108010015972 Elafin Proteins 0.000 description 6
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 6
- 229960005314 suramin Drugs 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 108010028780 Complement C3 Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 208000036640 Asperger disease Diseases 0.000 description 4
- 201000006062 Asperger syndrome Diseases 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
- FLYANDHDFRGGTM-PYJNHQTQSA-N Arg-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FLYANDHDFRGGTM-PYJNHQTQSA-N 0.000 description 3
- GMUYXHHJAGQHGB-TUBUOCAGSA-N Ile-Thr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GMUYXHHJAGQHGB-TUBUOCAGSA-N 0.000 description 3
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 3
- SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000012502 diagnostic product Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 108010076315 hexapeptide HWESAS Proteins 0.000 description 3
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940099204 ritalin Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001048718 Homo sapiens Elafin Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000008847 Serpin Human genes 0.000 description 2
- 108050000761 Serpin Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical class OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- IDIPWEYIBKUDNY-UHFFFAOYSA-N benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1 IDIPWEYIBKUDNY-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010000761 leucylarginine Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940106887 risperdal Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010061040 Childhood psychosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000364021 Tulsa Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007478 fluorogenic assay Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 238000002630 speech therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B20/00—Methods specially adapted for identifying library members
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42363610P | 2010-12-16 | 2010-12-16 | |
| US61/423,636 | 2010-12-16 | ||
| SE1051330-7 | 2010-12-16 | ||
| SE1051330 | 2010-12-16 | ||
| PCT/SE2011/051504 WO2012082056A1 (en) | 2010-12-16 | 2011-12-13 | Novel biomarker and uses thereof in diagnosis, treatment of autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2821908A1 CA2821908A1 (en) | 2012-06-21 |
| CA2821908C true CA2821908C (en) | 2018-09-18 |
Family
ID=45478452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2821908A Expired - Fee Related CA2821908C (en) | 2010-12-16 | 2011-12-13 | Novel biomarker and uses thereof in diagnosis, treatment of autism |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9347956B2 (enExample) |
| EP (1) | EP2651972B1 (enExample) |
| JP (1) | JP5960717B2 (enExample) |
| CN (1) | CN103328501B (enExample) |
| AU (1) | AU2011341776B2 (enExample) |
| CA (1) | CA2821908C (enExample) |
| ES (1) | ES2580136T3 (enExample) |
| WO (1) | WO2012082056A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| WO2014203188A2 (en) * | 2013-06-19 | 2014-12-24 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel assay |
| ES3067417T3 (en) | 2015-08-11 | 2026-05-21 | Cognoa Inc | Apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CN105738631B (zh) * | 2016-02-22 | 2017-10-20 | 西安交通大学 | 一种孤独症血清多肽标志物serpina5‑a及其应用 |
| WO2018013811A1 (en) * | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
| CN118609834A (zh) | 2016-11-14 | 2024-09-06 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| CN106596827B (zh) * | 2017-01-23 | 2019-06-07 | 上海知先生物科技有限公司 | Gal指标在自身免疫疾病治疗敏感性和疗效评估中的应用 |
| WO2018148262A1 (en) * | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
| KR101796891B1 (ko) * | 2017-02-08 | 2017-11-13 | 재단법인대구경북과학기술원 | 뇌 시상하부 세포에서 tspo에 의한 대사체 변화 분석방법 |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| WO2018148580A1 (en) * | 2017-02-09 | 2018-08-16 | Perfect Daylight Limited | Methods for autism spectrum disorder pharmacotherapy |
| US20220254461A1 (en) * | 2017-02-09 | 2022-08-11 | Cognoa, Inc. | Machine learning algorithms for data analysis and classification |
| GB201802116D0 (en) * | 2018-02-09 | 2018-03-28 | Univ Warwick | Methods for diagnosing an autistic spectrum disorder |
| ES2968823T3 (es) * | 2018-04-04 | 2024-05-14 | Univ Duke | Células estromales mesenquimales derivadas de tejido del cordón umbilical para su uso en el tratamiento de trastornos del espectro autista |
| CN109293762A (zh) * | 2018-10-17 | 2019-02-01 | 湖北民族学院 | DRC3f抗原多肽，抗DRC3f的多克隆抗体及应用 |
| CN109813912B (zh) * | 2019-01-04 | 2021-12-28 | 深圳大学 | 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用 |
| CN113873935B (zh) | 2019-03-22 | 2024-11-22 | 科格诺亚公司 | 个性化数字化治疗方法和装置 |
| WO2021046412A1 (en) | 2019-09-06 | 2021-03-11 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
| US20260188467A1 (en) * | 2024-12-27 | 2026-07-02 | Center for Social Dynamics, LLC | Parallel Processing Systems and Methods For Real-Time Multimodal Behavioral Classification Using Neural Networks With Dynamic Content Adaptation |
| WO2026163091A1 (en) | 2025-01-29 | 2026-08-06 | ENEA - Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile | Stage-specific combined fecal microrna panels as biomarkers for early diagnosis, clinical stratification and monitoring of alzheimer's disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998243B2 (en) | 2001-04-30 | 2006-02-14 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons |
| US6617308B2 (en) | 2001-04-30 | 2003-09-09 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons |
| US20020160532A1 (en) | 2001-04-30 | 2002-10-31 | George Jackowski | Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons |
| DE10158180A1 (de) * | 2001-11-28 | 2003-09-11 | Biovision Ag | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
| SE0300586L (sv) * | 2003-03-04 | 2004-09-05 | Forskarpatent I Syd Ab | Diagnos av autism |
| CN102984493B (zh) * | 2012-11-21 | 2016-03-02 | 华为终端有限公司 | 视频数据传输的方法、装置及通信设备 |
-
2011
- 2011-12-13 ES ES11808394.8T patent/ES2580136T3/es active Active
- 2011-12-13 EP EP11808394.8A patent/EP2651972B1/en not_active Not-in-force
- 2011-12-13 CN CN201180060249.6A patent/CN103328501B/zh not_active Expired - Fee Related
- 2011-12-13 WO PCT/SE2011/051504 patent/WO2012082056A1/en not_active Ceased
- 2011-12-13 AU AU2011341776A patent/AU2011341776B2/en not_active Ceased
- 2011-12-13 JP JP2013544428A patent/JP5960717B2/ja not_active Expired - Fee Related
- 2011-12-13 CA CA2821908A patent/CA2821908C/en not_active Expired - Fee Related
- 2011-12-13 US US13/994,671 patent/US9347956B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011341776A1 (en) | 2013-07-04 |
| WO2012082056A8 (en) | 2013-02-14 |
| CN103328501B (zh) | 2015-09-16 |
| US9347956B2 (en) | 2016-05-24 |
| CA2821908A1 (en) | 2012-06-21 |
| US20130267441A1 (en) | 2013-10-10 |
| CN103328501A (zh) | 2013-09-25 |
| WO2012082056A1 (en) | 2012-06-21 |
| AU2011341776B2 (en) | 2016-03-17 |
| ES2580136T3 (es) | 2016-08-19 |
| JP2014506244A (ja) | 2014-03-13 |
| EP2651972B1 (en) | 2016-04-06 |
| EP2651972A1 (en) | 2013-10-23 |
| JP5960717B2 (ja) | 2016-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011341776B2 (en) | Novel biomarker and uses thereof in diagnosis, treatment of autism | |
| JP2014506244A6 (ja) | 自閉症の診断、治療におけるバイオマーカーおよびその使用 | |
| JP5424331B2 (ja) | 肝疾患診断用バイオマーカー | |
| EP4220175A1 (en) | Proadm as marker indicating an adverse event | |
| WO2019149816A1 (en) | Method for the diagnosis of hereditary angioedema | |
| US20160011207A1 (en) | Diagnosis and therapy of chronic inflammation-induced disorders | |
| US11740245B2 (en) | Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients | |
| Snipsøyr et al. | Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis | |
| JPWO2006073195A1 (ja) | 糖尿病の予知・診断方法および糖尿病予知・診断用キット | |
| CN102539779A (zh) | 维生素d结合蛋白作为糖尿病标志物的应用 | |
| EP3637106B1 (en) | Lung cancer detection method | |
| US11435354B2 (en) | Adenocarcinoma detection method | |
| EP2728358B1 (en) | Haptoglobin alpha-r as marker for diagnosing lung cancer | |
| TWI845024B (zh) | 用以診斷和預斷大腸直腸癌的方法 | |
| US20130078653A1 (en) | Antibodies, compositions, and assays for detection of cardiac disease | |
| Klein et al. | Mischak, H., Peng, X.-R., Bascands, J.-L., and Schanstra, JP (2016) Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney International, 90 (5), pp. 1045-1055. | |
| WO2022091793A1 (ja) | 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発 | |
| KR20230035082A (ko) | 헵시딘의 레닌-기반 분석 | |
| van den Herik | Genetic and Hemostatic Risk Factors for Stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161123 |
|
| MKLA | Lapsed |
Effective date: 20191213 |